Beijing metabolic biotech QL Biopharm gets $72 million (500 million RMB) as it enters Phase 3 with a once-monthly GLP-1 injectable for obesity and diabetes, a Phase 2 GLP-1 tablet and a Phase 1 GLP-1/FGF21 shot for MASH
[DOI] [PMC free article] [PubMed] [Google Scholar] 152.Tan T.M., Field B.C., McCullough K.A., Troke R.C., Chambers E.S., Salem V., Gonzalez Maffe J., Baynes K.C., De Silva A., Viardot A., et al
Asian J Pharm Clin Res 10(5):313317 Abdellatif NA, Eltamany EE, El-Shenawy NS, Nafie MS, Hassan YM, Al-Eisa RA, Badr JM, Abdelhameed RF (2024) Cassia fistula leaves extract profiling and its emphasis on induced ulcerative colitis in male rats through inhibition of caspase 3 and cyclooxygenase-2
The preferred way of initiating insulin in people with type 2 diabetes is to add basal insulin to the existing pharmacological therapy, in conjunction with revisiting health behaviours and re-referral to DSMES
Alanazi, A
Monitor Your Fiber Intake Fiber will promote bowel movements, which can irritate them and cause more abdominal bloating